Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan M Alonso

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Medicina (Kaunas, Lithuania)|February 25, 2022
Flow Cytometry and Molecular Techniques Could Complement Morphological Detection of Leukemic Infiltration in Ascitic Fluids: A Case ReportInés Martínez-Alfonzo, Daniel Láinez-González, Laura Solán-Blanco, et al.
Scientific Reports|November 29, 2025
Mesenchymal stem cells-like as a prognostic biomarker in patients diagnosed with acute myeloid leukemiaTamara Castaño-Bonilla, Daniel Láinez-González, Juana Serrano, et al.
Plos One|July 14, 2017
PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phaseJuan M Alonso-Dominguez, Luis Felipe Casado, Eduardo Anguita, et al.
Annals of Hematology|February 3, 2026
The effects of the PHF6 gene mutation on myeloid neoplasms. A single-center cohort underpinned by a systematic review of literatureEdwin U Suárez, Carlos J Atencia, Fabio A Torres-Saavedra, et al.
Plos One|March 10, 2017
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemiaValentín García-Gutiérrez, María T Gómez-Casares, José M Puerta, et al.
Cancers|May 28, 2020
PLZF-RAR<sub>α</sub>, NPM1-RAR<sub>α</sub>, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature ReviewMarta Sobas, Maria Carme Talarn-Forcadell, David Martínez-Cuadrón, et al.
Disease Markers|September 2, 2022
No Evidence that <i>CD33</i> rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA GroupTamara Castaño-Bonilla, Eva Barragán, Claudia Sargas, et al.
Cancers|December 11, 2022
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry StudyRosa Ayala, Gonzalo Carreño-Tarragona, Eva Barragán, et al.
Haematologica|February 27, 2025
Prognostic relevance of variant allelic frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registryRafael Colmenares, Noemi Alvarez, Eva Barragan, et al.
Blood Cancer Journal|May 12, 2023
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA groupClaudia Sargas, Rosa Ayala, María J Larráyoz, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Medicina (Kaunas, Lithuania)|February 25, 2022
Flow Cytometry and Molecular Techniques Could Complement Morphological Detection of Leukemic Infiltration in Ascitic Fluids: A Case ReportInés Martínez-Alfonzo, Daniel Láinez-González, Laura Solán-Blanco, et al.
Scientific Reports|November 29, 2025
Mesenchymal stem cells-like as a prognostic biomarker in patients diagnosed with acute myeloid leukemiaTamara Castaño-Bonilla, Daniel Láinez-González, Juana Serrano, et al.
Plos One|July 14, 2017
PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phaseJuan M Alonso-Dominguez, Luis Felipe Casado, Eduardo Anguita, et al.
Annals of Hematology|February 3, 2026
The effects of the PHF6 gene mutation on myeloid neoplasms. A single-center cohort underpinned by a systematic review of literatureEdwin U Suárez, Carlos J Atencia, Fabio A Torres-Saavedra, et al.
Plos One|March 10, 2017
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemiaValentín García-Gutiérrez, María T Gómez-Casares, José M Puerta, et al.
Cancers|May 28, 2020
PLZF-RAR<sub>α</sub>, NPM1-RAR<sub>α</sub>, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature ReviewMarta Sobas, Maria Carme Talarn-Forcadell, David Martínez-Cuadrón, et al.
Disease Markers|September 2, 2022
No Evidence that <i>CD33</i> rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA GroupTamara Castaño-Bonilla, Eva Barragán, Claudia Sargas, et al.
Cancers|December 11, 2022
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry StudyRosa Ayala, Gonzalo Carreño-Tarragona, Eva Barragán, et al.
Haematologica|February 27, 2025
Prognostic relevance of variant allelic frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registryRafael Colmenares, Noemi Alvarez, Eva Barragan, et al.
Blood Cancer Journal|May 12, 2023
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA groupClaudia Sargas, Rosa Ayala, María J Larráyoz, et al.
Pageof 4